What question did this study set out to answer?

May 29, 2026Journal of Clinical Oncology

Refining clinical trial eligibility for minimal residual disease in patients with colorectal cancer: The MD Anderson INTERCEPT experience.

View Full Paper

Ask AI

Bookmark

Authors

SSSoumya ShekharThe University of Texas MD Anderson Cancer Center EÖEmerik ÖsterlundUniversity of Helsinki ABAlisha BentThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Randomized trial demonstrates recurrence outcomes in colorectal cancer patients with minimal residual disease, indicating a need for refined eligibility criteria.

Key Points

The aim is to improve identification of colorectal cancer patients with minimal residual disease for clinical trials using ctDNA.
Retrospective review of colorectal cancer patients enrolled in ctDNA intervention trials from 1/2019-12/2025.
Assessment of radiographic abnormalities and ctDNA levels at baseline to define minimal residual disease.
Analysis of recurrence-free survival (RFS) using Kaplan-Meier and Cox regression.
42 out of 54 enrolled patients (78%) experienced recurrence after treatment on a ctDNA intervention trial.
Median RFS was 8.1 months (95% CI 4.4 - 9.4), showing an association between undetected lesions and shorter RFS (4.2 vs 9.3 months; HR 1.96, 95% CI 1.04-3.70; p = 0.04).
Subclinical radiographic findings were misleadingly classified as 'benign' or 'post-procedural' in a majority of cases.

Cite This Study

Shekhar et al. (2026) studied this question.

synapsesocial.com/papers/6a192d2dfab5b468c4415fb8 https://doi.org/10.1200/jco.2026.44.16_suppl.3609

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates recurrence outcomes in colorectal cancer patients with minimal residual disease, indicating a need for refined eligibility criteria.

Refining clinical trial eligibility for minimal residual disease in patients with colorectal cancer: The MD Anderson INTERCEPT experience.

Discussion

Member takes

Implication

Key Points

Cite This Study

Refining clinical trial eligibility for minimal residual disease in patients with colorectal cancer: The MD Anderson INTERCEPT experience.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider